
    
      The study is a phase II, double-blind, placebo-controlled, multicenter study of rasagiline
      2mg/day. Subjects will be assigned to either active agent or placebo (3:1) for twelve months.
      Subjects will undergo outpatient evaluations at screening, baseline, and months 1, 2, 4, 6,
      8, 10 and 12 and telephone assessments at months 3, 5, 7 and 9. There will be a close-out
      phone call 30 days post month 12.
    
  